The Short discusses a 15% drop in Hims & Hers stock following an FDA announcement ending the shortage of Eli Lilly's weight ...

Hims & Hers is transforming telehealth with personalized medications, rapid subscription growth, and strong financials, ...

Craig Hettenbach, an analyst from Morgan Stanley, maintained the Buy rating on Hims & Hers Health (HIMS – Research Report). The associated ...

Hims & Hers Health (NYSE: HIMS) stock is on a downward trend on both macro trends and news about GLP-1s. But this is still a ...

Hims & Hers faces regulatory hurdles but shows strong business growth. Find out why HIMS stock is a "Hold" despite setbacks ...

CNBC’s Jim Cramer suggested on Tuesday that NVIDIA Corp. (NASDAQ:NVDA) may have reached a key turning point after the stock ...

BofA notes that yesterday morning, the FDA issued a new decision determining that the shortage of Eli Lilly’s (LLY) tirzepatide was resolved.

HIMS is on track for its worst single-session decline since Nov. 14, when Amazon.com (AMZN) entered the telehealth services ...

Morgan Stanley has initiated coverage on Hims & Hers Health, Inc. (NYSE:HIMS) with an Overweight rating and a price target of ...

In terms of liquidity and interest, the mean open interest for Hims & Hers Health options trades today is 3348.53 with a ...

Hims & Hers Health Inc (HIMS) stock saw a decline, ending the day at $26.36 which represents a decrease of $-2.19 or -7.67% from the prior close of $28.55. The stock opened at $26.04 and touched a low ...

Fmr LLC trimmed its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS – Free Report) by 99.2% in the third quarter, ...